Cleveland Skin Pathology
Share
Board Certified Dermatopathologists Cleveland Skin Pathology (CSP) was founded by Dr. Jerome R. Pomeranz in 1972.
At that time, he was Chairman of the Department of Dermatology at MetroHealth Medical Center in Cleveland, Ohio and an Associate Professor of Dermatology and Pathology at Case Western Reserve University School of Medicine. Highly respected by his colleagues, who often sought his expert opinion on cutaneous disease, he recognized the need for an independent laboratory solely dedicated to diagnosing
10/31/2016
Have a Safe and Happy Halloween from team CSP!!!
10/31/2016
More Halloween Shenanigans from our AMAZING STAFF!!
10/31/2016
Halloween Fun At CSP!!! Three Blind Mice Transcription Team
10/30/2015
Happy Halloween!
07/20/2015
Our laboratory has received accreditation from the College of American Pathologists.
The winning numbers are: 27, 55 and 88.
09/25/2014
Visit our website:
http://clevelandskinpathology.com
ClevelandSkinPathology.com We understand that diagnosing a skin biopsy is only part of what you need from a dermatopathology lab. Our team is made up of dermatologists with active academic and clinical practices.
CLEVELAND SKIN PATHOLOGY CHOSEN FOR NOVEL MELANOMA ASSAY!
A new clinically validated RNA-based diagnostic test myPath ™ Melanoma is now available from Myriad Genetic Laboratories to aid in the diagnosis of melanocytic lesions as being benign or malignant.
It is well known that melanoma is highly curable if diagnosed and treated in early stages. There is a marked difference in survival between localized and metastatic disease. Therefore, diagnostic markers that facilitate accurate diagnosis of melanoma at earlier stages could help prevent progression of the disease and reduce patient mortality. The myPath™ Melanoma assay features 23 unique molecular biomarkers whose gene expression profile has been shown to differentiate benign lesions from malignant melanoma with high sensitivity and specificity in multiple independent cohorts.
The development and training of the assay was conducted on 464 melanocytic lesions consisting of all major histological subtypes1. The assay was validated in a second cohort, with a total of 437 melanocytic lesions, also consisting of all major histological subtypes. In this validation study, the assay had a sensitivity of 90% and specificity of 91%.
A small group of dermatopathologists have been selected to have exclusive access to this test at no cost to the patient, physician, lab or third party payor for a limited time prior to the test being widely available. Cleveland Skin Pathology Laboratory has been selected as a test site and we wanted you to know that we may order this test on your patient, if appropriate (within the intended use) for the diagnostic process. If you would like more information or would like to obtain this test on a specific patient, please contact any of our pathologists and we will make arrangements to have the case sent to Myriad.
1 Clarke L et al. American Society of Dermatopathology 50th Annual Meeting. 2013.
Additional information available at www.Myriad.com or www.IsThisMelanoma.com
CSPL offers direct immunofluorescence testing on skin biopsies for the diagnosis of bullous and autoimmune diseases. Our panel of antibodies includes IgG, IgA, IgM, C3, and fibrinogen.
Transport media for immunofluorescence studies can be requested from CSPL.
Label the vial properly- Provide pertinent clinical information (perilesional, lesional, etc)- Do not place biopsy in formalin, even if only for a few seconds, the biopsy will be unusable- Biopsies in IF Fixative can remain refrigerated- Paired specimens (H&E) will optimize the diagnostic process. Please send the biopsy to our lab within one week after placing in fixative.
Turnaround Times:
Samples are completely processed within 3 business day after receipt.
Transport Medium:
We will supply you with the appropriate fixative (Michel’s media). A sample placed in formalin, even for a few seconds, could be read falsely negative.
Taking the Biopsy:
- A 4mm punch biopsy is preferred; however, a deep shave or saucerization into reticular dermis may also be acceptable for processing.
- Biopsies should be taken from peri-lesional skin (dermatitis herpertiformis, bullous pemphigoid, pemphigus) or involved skin in an erythematous area or an active border (LE, vasculitis, PCT, LPP).
- It is best to avoid older lesions or ulcers.
- For pemphigus or pemphigoid, if possible, avoid the lower extremity biopsies.
- Make sure the biopsy is not adherent to the lid or side of the vial and is fully immersed in fixative before tightening the vial lid.
Requisition forms can be downloaded by clicking below:
http://clevelandskinpathology.com/wp-content/uploads/2013/06/CSPL_REQFORM_519_UPDATED_V4.pdf
Click here to claim your Sponsored Listing.